Teleflex Incorporated (TFX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 225.69 |
| Open | 224.51 |
| Bid | 227.68 x 1000 |
| Ask | 233.93 x 1100 |
| Day's Range | 223.91 - 228.04 |
| 52 Week Range | 177.63 - 276.43 |
| Volume | |
| Avg. Volume | 309,861 |
| Market Cap | 10.699B |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | 26.60 |
| EPS (TTM) | 8.56 |
| Earnings Date | Feb 21, 2024 - Feb 26, 2024 |
| Forward Dividend & Yield | 1.36 (0.60%) |
| Ex-Dividend Date | Nov 14, 2023 |
| 1y Target Est | 240.75 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TFX
Related Research
- Teleflex IncorporatedTFX: Raising target price to $198.00TELEFLEX INC has an Investment Rating of SELL; a target price of $198.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moat4 days agoArgus Research
ZacksHere's Why You Should Retain Teleflex (TFX) Stock for Now
Investors remain optimistic about Teleflex (TFX) on the strength of the Vascular and Interventional businesses.
- Zacks
Teleflex (TFX) Enrolls First Patient in ACCESS-MANTA Registry
Teleflex's (TFX) ACCESS-MANTA Registry is likely to examine the contemporary on-label use of the MANTA VCD.
GlobeNewswireTeleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry
Registry Intends to Examine Contemporary On-Label Use of the MANTA™ Vascular Closure Device Including Appropriate Patient Selection and Proper Vascular AccessWAYNE, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical registry that is intended to examine and collect data on outcomes of contemporary on-label use of the MANTA™ Vascular Closure Device (VCD) in standard
